OrSense launches noninvasive haemoglobin monitor for pregnant women
This article was originally published in Clinica
Executive Summary
OrSense has launched its NBM200, a noninvasive point-of-care haemoglobin monitor for the detection of anaemia and haemorrhage during pregnancy. The disorder is common in pregnant women because they require more iron. Anaemia increases the risk of low neonatal birth weight and maternal mortality. The device, which is based on OrSense's proprietary occlusion spectroscopy technology, uses a ring-shaped probe that fits on the finger, thereby avoiding conventional blood sampling. It is CE marked for sale in Europe and has been submitted for US FDA 510(k) clearance. Nes Ziona, Israel-based OrSense has also developed a multiparameter monitoring system, NBM-200MP, which received 510(k) clearance in March (www.clinica.co.uk, 24 March 2010).